4.7 Article

Palliative Care in Advanced Cancer Patients: How and When?

期刊

ONCOLOGIST
卷 17, 期 2, 页码 267-273

出版社

WILEY
DOI: 10.1634/theoncologist.2011-0219

关键词

Early palliative care; Efficacy of palliative care; Symptom control; Cost of care; Quality care; Supportive care

类别

资金

  1. Ameritox
  2. Archimedes Pharmaceuticals
  3. Boston Scientific
  4. Covidien Mallinckrodt Inc.
  5. Endo Pharmaceuticals
  6. Forest Labs
  7. K-Pax Pharmaceuticals
  8. Meda Pharmaceuticals
  9. Medtronics
  10. Otsuka Pharma
  11. ProStrakan
  12. Purdue Pharma
  13. Salix
  14. St. Jude Medical
  15. Pfizer
  16. Lilly
  17. Bristol-Myers Squibb
  18. KangLaiTe
  19. Alexion
  20. Biovex
  21. DARA
  22. MiCo
  23. NIH
  24. Robert Wood Johnson Foundation
  25. AHRQ
  26. Amgen
  27. Helsinn Therapeutics
  28. Novartis
  29. National Institutes of Health through MD Anderson's Cancer Center [CA016672]

向作者/读者索取更多资源

Cancer patients develop severe physical and psychological symptoms as a result of their disease and treatment. Their families commonly suffer great emotional distress as a result of caregiving. Early palliative care access can improve symptom control and quality of life and reduce the cost of care. Preliminary results show that early palliative care access can also extend survival. Unfortunately, only a minority of cancer centers in the U.S. have the two most important resources for palliative care delivery: outpatient palliative care centers and inpatient palliative care units. In this article, we use a case presentation to discuss the impact of early palliative care access in light of the currently available evidence, and we recommend ways to improve early access to palliative care through education and research. The Oncologist 2012;17:267-273

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据